Supernus Pharmaceuticals Inc (SUPN) Q4 2018 Earnings Conference Call Transcript
SUPN earnings call for the period ending December 31, 2018.
Supernus Pharmaceuticals
SUPN
$36.37
$0.30
0.8%
BATS BZX Real Time Price as of April 22, 2019, 4:30 p.m.
View Interactive SUPN Charts
Supernus Pharmaceuticals Inc specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system or CNS diseases.
News & Analysis: Supernus Pharmaceuticals
All
Market Moves
Earnings
3 Top Small-Cap Stocks to Buy Right Now
Think software-as-a-service, neurology drugs, and marijuana.
3 Top Biotech Stocks to Buy in December
Find out why our healthcare contributors believe that these biotechs are great buys right now.
Here's Why Supernus Pharmaceuticals Is Sinking Today
Sometimes good news just isn't good enough.
3 Top Biotech Stocks to Buy in November
If you don't consider adding these biotech stocks to your portfolio this month, you could wind up missing out on an opportunity.
3 Top Biotech Stocks to Buy in September
These three relatively small biotechs could be just the ticket.
Why Supernus Pharmaceuticals, Inc. Is Falling Today
Shares sell off after the company posts mixed second-quarter results. Here's what investors need to know.
Why Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day
Despite Supernus' strong third-quarter earnings report, two possible concerns send the stock tumbling.
Why Supernus Pharmaceuticals' Shares Plummeted 23.4% Today
A change to phase 3 trials evaluating its lead product candidate SPN-810 fueled investors' pessimism.
3 Growth Stocks for Sharp Investors
On the hunt for a few stocks that hold upside potential? Here's why you should consider Starbucks, Wynn Resorts, and Supernus Pharmaceuticals.
